Bessemer Group
INM icon

Bessemer Group’s InMed Pharmaceuticals INM Stock Holding History

Bessemer Group’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed – – 2598
2025
Q2 		$0 Buy
+1
New +$3 ﹤0.01% 2518

Other funds holding INM

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Bessemer Group's INM Position: Q3 2025 in Review

Bessemer Group sold out of InMed Pharmaceuticals (INM) in Q3 2025, closing a stake of 1 share.

Bessemer Group first reported a position in INM in Q2 2025 and held it in 1 quarter. The position peaked at $0 in Q2 2025. 9 funds tracked by Wall St. Rank hold INM as of Q3 2025.

  • Bessemer Group reported no remaining InMed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Bessemer Group sold 1 InMed Pharmaceuticals share in Q3 2025.
  • Bessemer Group first reported a position in InMed Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Bessemer Group's InMed Pharmaceuticals position peaked at $0 in Q2 2025.
  • 9 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.